Response to de Vries et al.

  • Mrudu Herbert
  • , Zoheb B. Kazi
  • , Susan Richards
  • , Amy S. Rosenberg
  • , Priya S. Kishnani

Producción científica: Letterrevisión exhaustiva

2 Citas (Scopus)
Idioma originalEnglish
Páginas (desde-hasta)1281-1282
Número de páginas2
PublicaciónGenetics in Medicine
Volumen19
N.º11
DOI
EstadoPublished - nov 1 2017

Financiación

P.S.K. has received research/grant support from Sanofi Genzyme, Valerion Therapeutics, Shire Pharmaceuticals, Alexion, the National Institutes of Health, the Food and Drug Administration, and the Patient-Centered Outcomes Research Institute. She also receives consulting fees and honoraria from the Sanofi Genzyme, Shire Pharmaceuticals, Alexion Pharmaceuticals, Amicus Therapeutics and Roche. She serves as a member of the Pompe and Gaucher Disease Registry Advisory Board for Sanofi Genzyme, and is a Registry Board Member for Alexion Pharmaceuticals. She also serves on the Data Safety Monitoring Board for PTC Therapeutics. S.R. is an employee of Sanofi and owns stock in Sanofi. The other authors declare no conflict of interest.

Financiadores
National Institutes of Health (NIH)
U.S. Food and Drug Administration
Patient-Centered Outcomes Research Institute
Valerion Therapeutics
Sanofi Genzyme
Shire

    ASJC Scopus subject areas

    • Genetics(clinical)

    Citar esto